<DOC>
	<DOC>NCT01363336</DOC>
	<brief_summary>This study is a post-marketing surveillance in Japan, and it is a local prospective, company sponsored and observational study of patient who have been treated by Adalat CR for hypertension with diabetes and/or chronic kidney disease. The objective of this study is to assess safety and efficacy profile of using Adalat CR in real clinical practice. A total 2,000 patients will be recruited and be observed for 6 months. Then, patient of whom microalbumin urea and serum creatinine are continuously monitored are additionally followed for 6 months.</brief_summary>
	<brief_title>Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>Patient who are administered with Adalat CR for hypertension with diabetes and/or chronic kidney disease (CKD) CKD with stage 5 CDK with dialysis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Adalat</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Chronic kidney disease</keyword>
</DOC>